A.forall announces the launch of their fifth abbreviated new drug application (anda) and second “first cycle” fda approval

Minnetonka, minn.--(business wire)--a.forall's u.s. subsidiary milla pharmaceuticals inc. announced the launch of the group's generic version of precedex®, dexmedetomidine hydrochloride injection 200 mcg per 50 ml and 400 mcg per 100 ml in 0.9% sodium chloride in glass bottles by its partner sagent pharmaceuticals. dexmedetomidine hydrochloride injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. dexmedeto.
SLB Ratings Summary
SLB Quant Ranking